Pacific Edge Stock

Pacific Edge EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Pacific Edge (PEB.NZ) as of Aug 11, 2026 is -6.32. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -5.08 — a change of 24.32% (lower).

EV/FCF

-6.32

YoY

24.32%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Pacific Edge is 2026 -6.32 . EV/FCF (Enterprise Value to Free Cash Flow) of Pacific Edge was 2025 -5.08 . It decreases by 24.32% lower compared to the previous year.
Access this data via the Eulerpool API

Pacific Edge Stock analysis

What does Pacific Edge do? Pacific Edge Ltd is a company based in New Zealand specializing in the development and marketing of cancer diagnostic test systems. The company was founded in 2001 and has since become a leading provider of cancer detection systems in New Zealand and other countries. Pacific Edge's business model is based on the development and marketing of non-invasive diagnostic methods for early cancer detection. The tests offered are based on the analysis of urine samples, which are analyzed using state-of-the-art technologies to detect specific proteins in the urine that are typically associated with cancer. These tests enable doctors and patients to detect cancer at an early stage, increasing treatment and cure rates. Pacific Edge specializes in three main areas: urology, gynecology, and bladder cancer. The urology division focuses on the development of diagnostic tests for prostate cancer. It is one of the most common types of cancer in men, and early detection is known to increase the chance of a complete cure. Tests such as Cxbladder enable doctors to detect prostate cancer at an early stage. Pacific Edge's gynecology division focuses on the development of diagnostic tests for the early detection of cervical cancer. Currently, the Pap test is used in many countries to detect the presence of cancer cells in the cervix. However, the Cxbladder diagnostic test can detect the presence of certain proteins in the urine that indicate a cancerous condition, without the need for invasive procedures. The third pillar of Pacific Edge is the bladder cancer division. The Cxbladder test enables doctors to detect bladder cancer at an early stage. Currently, there are few effective screening methods for bladder cancer. However, the Cxbladder test can help detect bladder cancer at an early stage, improving treatment and cure rates. In addition to the three main areas, Pacific Edge also develops new diagnostic products for other types of cancer. These include cancers such as colon cancer, lung cancer, and kidney cancer, as well as rare cancers such as pancreatic cancer and esophageal cancer. Pacific Edge's products have already proven themselves in the medical community. They provide doctors and patients with an effective and cost-efficient way to detect cancer early. The company also conducts research and development to improve the accuracy and effectiveness of the tests offered. Pacific Edge is committed to expanding its business globally. It has already formed partnerships with some leading pharmaceutical and biotech companies to distribute its products on a global scale. The company has also established offices in Australia, the United States, and Singapore. In summary, Pacific Edge Ltd is a company specializing in the development and marketing of diagnostic tests for cancer. It focuses on the early detection of cancers such as prostate cancer, cervical cancer, and bladder cancer through the analysis of urine samples using state-of-the-art technologies. The company has established itself as a leading provider of cancer detection systems and conducts research and development to improve the accuracy and effectiveness of its products. Pacific Edge is committed to expanding its business globally and has already formed partnerships with leading companies in the pharmaceutical and biotech industry. Pacific Edge is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pacific Edge stock

EV/FCF (Enterprise Value to Free Cash Flow) of Pacific Edge is -6.32 in 2026.

EV/FCF (Enterprise Value to Free Cash Flow) of Pacific Edge changed from -5.08 to -6.32, representing a 24.32% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Pacific Edge since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Pacific Edge with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Pacific Edge

All Key Metrics — Pacific Edge